Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Joon Lee - Truist Salim Syed - Mizuho Luca Issi - RBC Catherine Novack - Jones Trading Madison El-Saadi - B.
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.07 per share a year ago.
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Wave Life Sciences (WVE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
1 Brand-New Big Reason to Buy This Biotech Stock Right Now
This stock currently has a good balance of risk and potential rewards.
What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now?
Does Wave Life Sciences (WVE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wave Life Sciences Rockets 70% on Historic RNA Editing Success
Wave Life Sciences Ltd. NASDAQ: WVE is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to reach a $10 billion market value by 2033.
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Wave Life Sciences Ltd. WVE stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder that causes low levels of a protein (AAT) that protects the lungs.
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.
